CXCR4 as a prognostic biomarker in gastrointestinal cancer: a meta-analysis.

Background

CXCR4 is a member of the C-X-C chemokine receptor family, which is associated with multiple types of cancer. Although it has been widely reported, the prognostic value of CXCR4 expression in gastrointestinal (GI) cancer remains controversial.

Methods

A meta-analysis was conducted to investigate the relationship between CXCR4 and prognosis of patients with GI cancer. Subgroup analysis was also performed according to tumour subtypes and heterogeneity test.

Results

A total of 24 studies including 3637 cases suggested that overexpression of CXCR4 is significantly associated with overall survival (OS) for patients with GI cancer (HR = 1.71, 95% CI = 1.45-2.03, p = 0.000). Subgroup analysis also indicated that high CXCR4 expression in oesophagus, gastric and colorectal cancer all predicted a worse prognosis (HR = 1.52, 95% CI = 1.26-1.84, p = 0.001 for oesophagus cancer; HR = 1.59, 95% CI = 1.10-2.30, p = 0.015 for gastric cancer; HR = 2.21, 95% CI = 1.56-3.14, p = 0.000 for colorectal cancer).

Conclusions

CXCR4 may serve as a prognostic indicator in GI cancer patients.